Measuring Effects of Alcohol on Brain Chemistry
Measuring Effects of Acute Ethanol on Human Brain Metabolites Using Magnetic Resonance Spectroscopy
2 other identifiers
observational
34
1 country
1
Brief Summary
Background: \- Studies show that alcohol changes the amount of many brain chemicals. These changes may be related to continued drinking, craving for alcohol, and relapse. This study will use magnetic resonance imaging (MRI) to look at brain areas and brain chemistry during an infusion of alcohol. It will also study how changes in brain chemistry relate to participant reports of feeling drunk. Objectives: \- To use magnetic resonance imaging to measure the effect of alcohol on brain chemistry Eligibility:
- Individuals between 21 and 45 years of age.
- Participants will be either light drinkers (1 to 14 standard alcoholic drinks per week) or heavy drinkers (20 to 40 standard alcoholic drinks per week). A standard drink is a 12-ounce beer, a 4-ounce glass of wine, or a shot of liquor.
- Participants must be able to go without alcohol for at least 3 days in a row without severe withdrawal symptoms. Design:
- This study requires two or three outpatient visits to the NIH Clinical Center.
- Participants will have a physical exam and medical history. Blood and urine samples will be collected. Participants' alcohol drinking habits will also be assessed to determine whether they may have an alcohol use disorder.
- At the first study visit, participants will have an infusion of alcohol. Blood samples will be collected to measure blood alcohol levels.
- The MRI study visit will take place about 3 days after the first study visit. Participants will have an MRI scan of the brain, followed by an infusion of alcohol and another scan. Blood samples will be collected.
- Participants will complete questionnaires before and after each infusion to measure their response to alcohol.
- Heavy drinkers will come to the clinic for a third visit to discuss possible future treatment and any risky behavior associated with their high levels of alcohol use.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2011
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 22, 2011
CompletedFirst Submitted
Initial submission to the registry
December 14, 2011
CompletedFirst Posted
Study publicly available on registry
December 15, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
February 24, 2015
CompletedDecember 3, 2019
February 24, 2015
December 14, 2011
November 30, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
What is the correlation between measured blood and breath alcohol level and ethanol level concentration computed from MRS.
End of study
Secondary Outcomes (2)
Does ethanol administration similarly affect the metabolite activities in all the regions of the brain Gray and White matter?
End of study
Measure: Does ethanol metabolite concentration correlate with any of subjective effects of ethanol as measured by response to DEQ questions?
End of study
Eligibility Criteria
You may qualify if:
- In good health as determined by medical history, physical exam, ECG and lab tests;
- Between 21 and 45 years of age;
- Currently consuming between 1 and 10 drinks per week for females and 1 and 14 drinks per week for males.
You may not qualify if:
- Have liver function tests (AST, ALT, GGT, ALP) 3-times the upper limit of normal (ULN); or have Total Bilirubin above 1.5 ULN and Albumin below 3.5 g/dL.
- Have fulfilled DSM-IV criteria for a current or past major psychiatric disorder including alcohol or other substance dependnece (excluding nicotine);
- Have a Body Mass Index (BMI) value over 35;
- Unable to stop taking any prescribed, non-prescribed, or over-the-counter medication or drugs 3 days prior to study days (excluding oral contraceptive agents). If a subject is taking a prescribed medication (excluding oral contraceptive agents) that is not take-as-needed they will be excluded from participation;
- Are pregnant, as determined by a negative pregnancy test, or lactating;
- Report to have a "facial flushing" response to the consumption of alcohol;
- Have never consumed at least two standard drinks of alcohol within one hour;
- Regular tobacco users will be excluded from the study in order to avoid nicotine withdrawal symptoms. Occasional (not daily) use of tobacco products is acceptable;
- Unwilling to abstain from alcohol for at least 2 days prior to the studies.
- In good health as determined by medical history, physical exam, ECG and lab tests;
- Between 21 and 45 years of age;
- Currently consuming 15+ drinks for females and 20+ drinks for males;
- Not regularly abstinent for more than 3 days per week, but have abstained from alcohol for 3 consecutive days without experiencing withdrawal symptoms;
- Able to provide a plausible history that they can abstain from alcohol without significant withdrawal symptoms when coming to the clinic. In addition, participants will be asked to quantify their worst withdrawal symptoms using the Clinical Institute Withdrawal Assessment (CIWA) Instrument. Participants who score 8 or above will not be enrolled in the protocol;
- Not seeking treatment for their alcohol consumption.
- +9 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Related Publications (3)
Beckmann CF, Smith SM. Tensorial extensions of independent component analysis for multisubject FMRI analysis. Neuroimage. 2005 Mar;25(1):294-311. doi: 10.1016/j.neuroimage.2004.10.043. Epub 2005 Jan 8.
PMID: 15734364BACKGROUNDRomanos GE, Schroter-Kermani C, Bernimoulin JP. [Collagen as a basic element of the periodontium: immunohistochemical aspects in the human and animals. 2. Cementum and periodontal ligament]. Parodontol. 1991 Feb;2(1):47-59. German.
PMID: 1854918BACKGROUNDBehrens TE, Berg HJ, Jbabdi S, Rushworth MF, Woolrich MW. Probabilistic diffusion tractography with multiple fibre orientations: What can we gain? Neuroimage. 2007 Jan 1;34(1):144-55. doi: 10.1016/j.neuroimage.2006.09.018. Epub 2006 Oct 27.
PMID: 17070705BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Reza Momenan, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- NIH
Study Record Dates
First Submitted
December 14, 2011
First Posted
December 15, 2011
Study Start
November 22, 2011
Study Completion
February 24, 2015
Last Updated
December 3, 2019
Record last verified: 2015-02-24